The field of cardiology is in mourning. A drug that much of the cardiovascular world expected to become a blockbuster just failed in a huge trial. The past president of the American Society for ...
An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results